About Check-Cap

A Foundation in Medical Innovation

Check-Cap Ltd. has a legacy of pioneering medical device technology. Today, the company is entering its next chapter through a transformative merger with MBody AI Corp.

Company Background

About Check-Cap Ltd.

Check-Cap Ltd. is an Israeli clinical-stage medical diagnostics company that developed the C-Scan® System, an innovative ingestible capsule designed for preparation-free colorectal cancer screening. Founded with the mission of removing barriers to colorectal cancer screening, the company has been listed on NASDAQ since 2015.

In September 2025, Check-Cap announced a definitive merger agreement with MBody AI Corp., marking a strategic transformation from medical devices to embodied artificial intelligence. The company's NASDAQ ticker changed from CHEK to MBAI in December 2025 to reflect this new direction.

Company at a Glance

  • Founded: 2004, Isfiya, Israel
  • Listed: NASDAQ since 2015
  • Ticker: MBAI (formerly CHEK)
  • Sector: Medical Diagnostics → Embodied AI (upon completion of the merger, subject to closing conditions)
  • Headquarters: 29 Abba Hushi Ave., Isfiya, Israel
Medical Device Technology

The C-Scan® System

An innovative approach to colorectal cancer screening designed to improve patient compliance.

The C-Scan System — an ingestible capsule for preparation-free colorectal cancer screening

How It Works

The C-Scan System is an ingestible X-ray capsule designed to generate 3D structural maps of the inner lining of the colon as it passes naturally through the gastrointestinal tract. The system was developed to address a critical gap in colorectal cancer screening: patient avoidance of traditional colonoscopy due to the preparation process.

Unlike traditional screening methods, the C-Scan capsule requires no bowel preparation, no sedation, and no time off work. This removes the primary barriers that prevent millions from getting screened.

Key Features

  • Preparation-Free: No bowel prep, fasting, or dietary restrictions required
  • Non-Invasive: Ingestible capsule passes naturally through the GI tract
  • No Sedation: Patients remain fully functional during the screening process
  • X-Ray Imaging: Ultra-low-dose X-ray technology creates structural maps of the colon
  • 3D Mapping: Generates detailed 3D models for physician review
The Problem

Why Screening Matters

Colorectal cancer remains one of the most preventable yet underscreened cancers worldwide.

#2
Leading cause of cancer-related death in the U.S.
150K+
New CRC cases diagnosed annually in the U.S.
50M+
Americans not up to date on CRC screening
90%
Survival rate when CRC is detected early
Looking Forward

A New Chapter

While Check-Cap's foundation lies in medical innovation, the company's future is in embodied AI. The merger with MBody AI Corp. represents a strategic transformation, leveraging Check-Cap's public company infrastructure and NASDAQ listing to bring MBody AI's Orchestrator™ platform to the public markets. The merger agreement is expected to close in the first half of 2026, subject to customary closing conditions.

View the Transaction Learn About MBody AI

Forward-Looking Statements: This website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied. Forward-looking statements include, but are not limited to, statements regarding the proposed merger with MBody AI Corp., the expected timing of completion of the transaction, the combined company's anticipated operations, and the expected benefits of the transaction. These statements are subject to risks, including the ability to satisfy closing conditions, NASDAQ listing approval, regulatory approvals, and other factors described in Check-Cap's filings with the SEC, including its Annual Report on Form 20-F and the F-1 Registration Statement. The C-Scan® System is not approved in the United States and is currently an investigational device. Investors are urged to review these filings, available at the Investor Relations page, for a more complete discussion of risks and uncertainties. Check-Cap assumes no obligation to update forward-looking statements except as required by law.

Additional Information: In connection with the proposed merger, Check-Cap Ltd. has filed a Registration Statement on Form F-1 and a Proxy Statement with the SEC. Investors and security holders are urged to read these documents and any amendments or supplements thereto, as well as other relevant documents filed with the SEC, because they contain important information about the proposed transaction. These documents are available free of charge at the SEC's website at www.sec.gov and on the Company's Investor Relations page.

No Offer or Solicitation: This website does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any securities of Check-Cap Ltd. or any other entity. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.